πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

86 results for β€œTG” Clear

  1. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  2. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  3. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  4. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  5. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  6. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  7. evinacumab

    Regeneron UK Limited

    Severe Hypertriglyceridemia (sHTG)

    phase 2 small molecule completed

    1 trial

  8. rabbit ATG, Cyclosporine, Levamisole

    China SXT Pharmaceuticals

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial

  9. A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

    Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH

    Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

    phase 1 other active

    1 trial

  10. APOC-III-L-Rx

    IONIS PHARMACEUTICALS INC

    Elevated Triglycerides (TG)

    phase 1 small molecule completed

    1 trial

  11. Azercabtagene zapreleucel (azer-cel)

    TG THERAPEUTICS, INC.

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial

  12. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  13. DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  14. GPC3 and/or TGFΞ² targeting CAR-T cells

    First Tracks Biotherapeutics

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  15. NM1F Injection

    TG THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  16. PTG-100

    Protagonist Therapeutics, Inc

    Celiac Disease

    phase 1 small molecule completed

    1 trial

  17. PTG-300

    Protagonist Therapeutics, Inc

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. Relacorilant (3x100 mg softgel capsules)

    CORCEPT THERAPEUTICS INC

    Healthy

    phase 1 small molecule completed

    1 trial

  19. TG-0054

    Structure Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  20. TG-1701

    TG THERAPEUTICS, INC.

    Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  21. TG-1801

    TG THERAPEUTICS, INC.

    B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  22. TG-1801

    TG THERAPEUTICS, INC.

    CLL

    phase 1 mab terminated

    1 trial

  23. TGD001 SAD study in healthy volunteers

    Pharma Mar S.A.

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  24. TGI-5

    TG THERAPEUTICS, INC.

    CRC (Colorectal Cancer)

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources